In Vitro Lung Model Market: Significant Growth in Research Funding

According to The Insight Partners market research titled ‘In Vitro Lung Model to 2027 – Global Analysis and Forecasts by Type, and Application.’ The global in vitro lung model market is anticipated to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018. The market is anticipated to grow with a CAGR of 16.2% from 2019-2027. The report provides the trends prevailing in the global In vitro lung model market and the factors driving the market along with those that act as hindrances.

The report provides trends prevailing in the global in vitro lung model market and the factors driving the market along with those that act as hindrances. The market for in vitro lung model is expected to grow, owing to factors such as significant growth in research funding, and increasing adoption of 3d model systems for in vitro studies. Moreover, rising research on lung diseases are likely to have a positive impact on the growth of the market in the coming years.

The market for in vitro lung model is expected to grow, owing to factors such as significant growth in research funding, and increasing adoption of 3d model systems for in vitro studies. Moreover, growing research on lung diseases are likely to have a positive impact on the growth of the market in the coming years.

Get sample Research on In Vitro Lung Model Market at: https://www.theinsightpartners.com/sample/TIPRE00006695/

In Vitro Lung Model Market Competitive Landscape

The leading companies operating in the in vitro lung model market include Epithelix Sàrl, MATTEK, LONZA, InSphero, Emulate, Inc., AlveoliX AG, Thermo Fisher Scientific Inc, PromoCell GmbH, Merck KGaA, and Horizon Discovery Group plc. among others. The market has observed various organic as well as inorganic developments during recent years in the in vitro lung model market. For instance, in October 2017, InSphero AG and Charles River Laboratories International, Inc. announced a partnership through which Charles River will license its collection of patient-derived xenograft (PDX) tumors to InSphero.

Significant Growth in Research Funding

Research and development is crucial part of the company’s business. The biotechnology companies focus on the research and development (R&D) to come up with new molecules for various therapeutic applications with the greatest medical and commercial potential. The companies are invest majorly on the R&Ds with the aim of developing high quality and innovative products to the market. As per the report of Pharmaceutical Research and Manufacturers of America (PhRMA), the Research and Development expenditure of the biopharmaceutical companies has increased from US$ 49.6 billion 2012 to US$ 58.8 billion in 2015. R&D spending by the major companies operating in this market has increased over the years.

Around 60 percent of investigational drugs fail in clinical trials due to a lack of efficiency, in spite of promising results in pre-clinical studies using animal research models. Thus, in September 2017, NIH funded $15 million to develop 3-D human tissue models.

Furthermore, InSphero AG, an innovative provider of 3D cell-based platforms for drug discovery and efficacy testing, received USD 10 million to further improve its discovery platforms for metabolic diseases and cancer.

Rising Research on Lung Diseases

The cases of asthma, lung cancer, and COPD has been growing across the globe at a significant rate. Thus there is a growing need to study lung diseases specifically. Since early 2010’s the practices of creating lab-grown organ buds, mostly referred to as ‘organoids’, have become more popular. These organ buds are miniature organ-like structures that are maintained in the lab, and researchers are able to grow these organoids, which resembles human body tissues. Lung diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) among others are significantly causing death and illness worldwide. In April 2017, researchers at the University of Michigan Medical School published an “In Vitro Models to Study Human Lung Development, Disease, and Homeostasis” report in PhysIOL journal. The report discussed the current advances in generating in vitro human lung models using cell lines, primary human tissue, and human pluripotent stem cell derived lung tissue. Moreover, Lung cancer cell lines have made a significant contribution to lung cancer research and biomedical discovery. The high similarities between lung cancer cell lines and the lung tumor helps in discovering new drug molecules.

The global in vitro lung model market, based on the type, is segmented into 2D, and 3D. In 2018, the 3D segment held the largest market share of the in vitro lung model market. This segment is also projected to dominate the market in 2027 as 3D in vitro lung models enhance the expression of gene regulation, soluble factors, and response to therapeutic agents.

Buy Complete Report of In Vitro Lung Model Market at: https://www.theinsightpartners.com/buy/TIPRE00006695/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Back to news